Registry of Osteogenesis Imperfecta
Launched by LUCA SANGIORGI · Oct 3, 2019
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
The Registry of Osteogenesis Imperfecta (ROI) is a clinical trial designed to gather and study information about people with Osteogenesis Imperfecta (OI), a genetic condition that causes fragile bones. The goal of this registry is to collect various types of data, including personal details, medical history, genetic information, and details about surgeries. By combining all this information, researchers hope to better understand how OI affects patients and how different genetic factors may influence the condition's severity and symptoms.
Anyone diagnosed with Osteogenesis Imperfecta, including those identified before birth, is eligible to participate in this study. However, individuals with unrelated health conditions will not be included. Participants can expect to provide information about their health history and undergo assessments related to their condition. This registry aims to improve care and treatment options for those living with OI by creating a comprehensive understanding of the disease.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • All Osteogenesis Imperfecta patients, including prenatal and fetal diagnosis of Osteogenesis Imperfecta
- Exclusion Criteria:
- • Any condition unrelated to Osteogenesis Imperfecta
About Luca Sangiorgi
Luca Sangiorgi is a dedicated clinical trial sponsor committed to advancing medical research and innovation. With a focus on developing novel therapies, Luca Sangiorgi leads initiatives that emphasize patient safety, scientific rigor, and ethical standards. The organization collaborates with leading research institutions and healthcare professionals to conduct clinical trials across various therapeutic areas, aiming to bring impactful treatments to market. Through strategic partnerships and a strong emphasis on data integrity, Luca Sangiorgi strives to enhance patient outcomes and contribute to the evolution of healthcare.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Bologna, Emilia Romagna, Italy
Patients applied
Trial Officials
Luca Sangiorgi, PhD
Principal Investigator
Istituto Ortopedico Rizzoli
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials